What It Is
Cerebrolysin differs from most peptides covered on this site in that it isn't one defined amino-acid sequence — it is a biological mixture of low-molecular-weight peptide fragments and free amino acids derived from porcine (pig) brain tissue.[1] Sold outside the United States as an injectable solution, it has been studied for decades in neurological conditions including ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease.[3] Because it is a biological mixture rather than a single synthesized molecule, its exact composition can vary somewhat by manufacturing batch.
How It Works
Cerebrolysin's proposed mechanism is described as “multimodal,” meaning researchers hypothesize several simultaneous effects rather than one clean receptor pathway. The leading hypothesis is that it acts somewhat like the body's own neurotrophic factors — proteins such as BDNF, nerve growth factor, and GDNF that support neuron survival and synaptic connections — and product literature also describes proposed effects on sonic hedgehog signaling, a pathway linked to neural repair.[2] In laboratory neuron cultures exposed to glutamate, a chemical that becomes toxic to brain cells after injury, Cerebrolysin reduced markers of cell damage.[20] These are plausible explanations for continued research interest, not proof of a specific human clinical benefit.
What the Research Shows
Cerebrolysin has one of the larger human trial records of any compound covered on this site, and the results are genuinely mixed. A 2023 Cochrane systematic review of seven trials (1,773 participants) in acute ischemic stroke concluded that Cerebrolysin probably does not reduce the risk of death, and that non-fatal serious adverse events were probably more common with it than with standard care.[3] A meta-analysis of nine stroke-recovery trials reported some early neurological-improvement signals, and a pooled analysis of the CAPTAIN trial series in moderate-to-severe traumatic brain injury reported a small-to-medium benefit at 30 and 90 days.[10][11] In Alzheimer's disease, one placebo-controlled trial found a significant difference on a global clinical-impression scale at 12 weeks — a single trial, not a consistent pattern.[14] A separate Cochrane review of vascular dementia trials described the evidence base as weak and called for better-designed studies.[13] Overall, this compound has real clinical trial data, unusual for the peptides covered here, but results vary by condition and do not consistently show a mortality or disease-modifying benefit.
Safety & Side Effects
In dementia trials, Cerebrolysin has generally been described as well tolerated, with dizziness or vertigo the most common complaint. In one Alzheimer's disease trial, adverse events actually occurred slightly more often with placebo (73%) than with Cerebrolysin (64%), including headache, dizziness, and anxiety.[14] However, the 2023 Cochrane stroke review flagged a probable increase in non-fatal serious adverse events, and a published case report described a life-threatening anaphylactic reaction after intravenous administration.[3][24] Labeling used outside the United States lists several contraindications:
- Hypersensitivity to any component of the product
- Epilepsy or seizure disorders
- Severe renal impairment
Pregnancy, breastfeeding, and seizure history warrant clinician review given the limited data available.[2]
Regulatory Status
Cerebrolysin is not FDA-approved for any use in the United States. FDA's orphan drug database lists an earlier orphan-designation entry for a “peptide fraction derived from porcine brain protein” as not approved for that indication, and a separate FDA warning letter to a compounding pharmacy stated that Cerebrolysin is not a component of any FDA-approved drug.[4][6] Outside the U.S. — including Russia, other parts of Eastern Europe, and China — Cerebrolysin is marketed with labeled indications for stroke and dementia, but approval and labeling differ substantially by country, and personal importation into the U.S. generally runs against FDA import rules.[5]